Introduction
Acute myeloid leukemia (AML) is characterized by failed differentiation and uncontrolled proliferation of hematopoietic myeloid progenitor cells. With modern treatments, the majority of patients with AML obtain a complete remission (CR), but more than two-thirds of adult AML patients relapse and the 5-year survival rate is only 30-40%; less than 15% in patients above the age of 60 [1] . The most common treatment for AML currently in use is a combination of the nucleoside analog cytosine arabinoside (AraC) and an anthracycline such as daunorubicin or idarubicin, followed by consolidation chemotherapy and/or stem cell transplantation.
Cytogenetic characterization of AML at diagnosis is crucial for treatment strategies and prognosis. Based on cytogenetic aberrations, patients can be stratified into high, intermediate, and low-risk patient groups [2, 3] . However, almost half of the AML patients do not show any cytogenetic aberrations and are referred to as normal karyotype AML (NK-AML) [2] .
Patients (<70 years) in this group have a 5-year overall survival (OS) of 35-40%, but this intermediate risk group is very heterogeneous with respect to treatment response and risk of relapse [4] .
A number of mutations are known to predict response and outcome in the NK-AML group [5, 6] . The fms-like tyrosine kinase 3 gene (FLT3) is mutated and constitutively active in about 30% of the AML patients, the majority of these mutations being internal tandem duplications (ITD) in the coding region for the juxtamembrane loop of this enzyme [7, 8] . The FLT3-ITD mutation in NK-AML is associated with higher leukocyte and blast counts, increased relapse rates and decreased OS [9, 10] .
On the other hand, mutation in the nucleolar protein nucleophosmin, encoded by the NPM1 gene, is a favorable prognostic factor for achieving CR [11] . This gene is mutated in approximately 50-60% of NK-AML patients. However, this mutation provides no protective benefit when it occurs together with the ITD of FLT3, which is the case in approximately 40% of patients with NPM1 mutations [5] . As with NPM1 mutations, CCAAT/enhancer binding protein alpha (CEBPA) gene mutations, found in around 10% of all AML patients, are associated with a favorable prognosis in de novo NK-AML but only in the absence of FLT3-ITD [12] .
One reason for the poor treatment outcome in AML could be deregulated expression of AraC-metabolizing enzymes. AraC is activated intracellularly by the enzyme deoxycytidine kinase (DCK), which converts it to the triphosphate, Ara-CTP, and poor treatment outcome and chemotherapy resistance might be due to decreased expression or activity of this enzyme [13] . There are also several enzymes responsible for the inactivation of AraC, including cytidine deaminase (CDA) and 5´-nucleotidases, and altered activity of these enzymes can lead to decreased sensitivity to AraC [14, 15] . The balance of these enzyme activities determines the cellular concentration of active Ara-CTP, which is a metabolite that varies widely in patients with AML [16] . The ratio of deoxycytidine to cytosolic 5´-nucleotidase II (cN-II) expression has been shown to correlate with intracellular production of Ara-CTP in primary AML cells [17] and is a predictor of survival in AML patients treated with AraC [18] .
Single nucleotide polymorphisms (SNPs) can significantly alter the expression and activity of these drug-metabolizing enzymes [19] [20] [21] [22] [23] . Provided confirmation in clinical trials, SNPs may serve as biomarkers guiding the clinician in the choice and dosing of drugs according to the drug-metabolizing capacity of the patient. Hopefully, this will lead to less drug resistance, reduce the toxic side effects of treatment, and increase survival rates.
In this study we investigated the potential of polymorphisms in the DCK, CDA, and cN-II genes to act as markers of drug sensitivity and prognosis in 205 de novo NK-AML patients.
Our findings indicate that CDA and cN-II polymorphisms may have potential as biomarkers for risk stratification in NK-AML patients.
Methods

Patients
The study was approved by the local Ethics Committees and conducted in compliance with the Helsinki declaration. All patients provided informed consent to be included in this study. for 7 days combined with either daunorubicin or idarubicin [24] . In addition to chemotherapy, fifty-seven patients were consolidated with allogeneic hematopoietic stem cell transplants (allo-SCT). Chemotherapy response, defined as morphological CR or noncomplete remission (no CR), was evaluated according to the International Working Group criteria, and patients were followed up for up to 4 years. Median censoring time was 10 months (0.03-48 months); patients treated by allo-SCT were censored at the time of transplantation. Without censoring at time of transplantation, median censoring time was 17 months (0.03-48 months). 
SNP genotyping
The two CDA SNPs, 79A>C (rs2072671) and -451C>T (rs532545), and the cN-II SNP 7A>G
(rs10883841) were evaluated using TaqMan SNP Genotyping Assays according to the manufacturer´s instructions with the exception that we used a total reaction volume of 10 L.
The DCK SNP 3´UTR 948T>C (rs4643786) was detected using PCR followed by according to the manufacturer's instructions and as previously described [25] . In brief, the amplified and biotinylated PCR product was isolated with a Vacuum Prep Workstation duplicate and including drug free controls [28, 29] . After culturing during 96 h, the cell viability was determined by measuring the intracellular ATP concentrations using a bioluminescence assay as previously described [30] . The half maximal inhibitory concentrations expressed as IC50 values were calculated by comparing the ATP concentrations to those in the drug free controls.
DNA methylation assay
Global DNA methylation was detected using the colorimetric version of the MethylFlash Kaplan-Meier analysis was applied together with the log-rank test to determine the significance of differences in survival times. These tests were performed with both the entire material and with the data stratified by FLT3 and NPM1 status. Survival analysis was 
Results
No differences in genotype frequencies between NK-AML patients and controls
All 205 patients with de novo NK-AML were successfully genotyped for SNPs in CDA (79A>C and -451C>T) and DCK (3´UTR 948T>C). cN-II (7A>G) genotyping was successful for all but 3 patients. Data on FLT3-ITD and NPM1 mutations were available for 203
patients. No significant differences in genotype distributions between patients and the reference population were found (Table II, genotypes. Heterozygous DCK T/C patients were significantly younger than DCK T/T patients, mean age at diagnosis 48 and 60 years, respectively (p=0.007).
No significant effects of the SNPs on treatment response
There were no significant differences between genotypes in terms of treatment response for the CDA or cN-II SNPs. For the DCK 3´UTR 948T>C SNP, all 16 patients with the T/C genotype achieved CR compared to 152 out of 185 of the homozygous T/T patients, but this difference was not statistically significant (p = 0.08, Table III, supplemental online   material) . Notably, the heterozygous T/C patients were also more frequently transplanted than T/T patients (50% and 26%, respectively, p=0.047).
Impact on survival of the CDA and cN-II SNPs
The SNPs and the FLT3 and NPM1 mutations were analyzed for any correlations with progression free survival (PFS) or OS.
No significant differences in OS were seen for any of the SNPs when analyzing the entire material. However, when the patients were stratified according to FLT3 status, a significant effect on OS was observed both for CDA 79A>C and -451C>T SNPs in the FLT3-ITDpositive patients. This was the case with as well as without censoring patients at time of allo-SCT, although some survival differences between genotypes were indicated in the unstratified material for CDA 79A>C when censoring at time of allo-SCT was not applied The T allele of the CDA -451C>T SNP has previously been shown to result in altered enzyme expression and activity [19, 31] . A study by Mahlknecht et al. reported a higher incidence of AraC-related grade III and grade IV liver toxicity in patients with the CDA 79A>C variant allele and a shorter survival time in CDA -451T/T AML patients [22] . This study is in accordance with our results; however, no toxicity data were available on our patients. The
CDA 79C/C variant has been reported to result in lower CDA allelic expression [19] , decreased enzyme activity [32] , poor outcome in patients with non-small cell lung cancer [33] , and reduced in vitro AraC deamination [34] , while other studies report a higher CDA activity in the 79C variants [23] . We could not investigate CDA phenotypes in our patients, which would have provided further explanations to the survival differences seen between the CDA genotypes. However, despite differences in explanatory hypotheses, most studies describe a worse outcome in homozygous 79C/C patients, which is in accordance with our findings. The impact of SNPs affecting CDA activity may also depend on drug dosage. In patients receiving lower dose AraC, a decrease in CDA activity might result in improved treatment response, while in higher dose regimens it could increase the risk of toxicities.
Surprisingly, none of the SNPs affected the sensitivity to AraC in vitro. Instead, the CDA variants were associated with an increased sensitivity to topoisomerase inhibitors. There may be methodological explanations to the lack of any detectable difference in AraC sensitivity.
AraC acts on cells mainly in the S-phase, and in this short term incubation assay, cells are mainly kept alive without extensive cell division. To achieve significant cytotoxic effects in vitro, AraC concentrations higher than those achieved in vivo are required, which in turn may overcome any differential enzyme activity between variants. Influence of CDA polymorphisms on AraC sensitivity should therefore not be excluded based on our in vitro results. Why the effect of topoisomerase inhibitors would be enhanced in the CDA variants remains a question. Cytidine deamination was first discovered as a mechanism of RNA editing [35] , allowing for modification of mRNA transcripts in order to alter the amount of gene product without directly affecting the genes. The activation-induced cytidine deaminase has been shown to reduce the expression of topoisomerase by suppressing its mRNA through deamination [36] . We speculate, therefore, that an altered CDA activity may lead to altered expression of topoisomerase enzymes in the cells and to a potentiation of drug effect.
Unfortunately, we did not have sufficient amounts of RNA to measure the expression of topoisomerase mRNA.
Another possible mechanism explaining the differential drug sensitivity could be that CDA might affect the degree of DNA methylation, and thereby the amount of DNA available to these drugs. Pharmacological inhibition of CDA reduces the degree of DNA methylation [37, 38] and we speculated, therefore, that individuals carrying the CDA variant alleles may not only have reduced CDA activity, but also overall reductions in DNA methylation. We found significant differences in global methylation between cells from patients homozygous for both CDA SNPs (79A/A and -451C/C) and patients heterozygous in both positions (p = 0.018). The group with the alternative homozygous genotype (79C/C together with -451T/T) was limited in number but appeared visually to be less methylated than the other two groups.
We speculate, therefore, that CDA may somehow take part in the DNA methylation process and thereby affect topoisomerase inhibitor sensitivity.
The cN-II 7A>G SNP did not show any correlation to response, outcome, or cytotoxicity in the entire material, although some differences in mRNA expression have been shown previously between cN-II genetic variants [19] . Some survival differences were seen in FLT3-ITD-negative patients, where the cN-II G allele seemed to be associated with shorter OS, but this did not hold in the multivariable analysis.
It was interesting that patients heterozygous for the DCK 3´UTR 948C>T SNP all achieved initial CR. Lamba (2007) showed that polymorphisms in the 3´UTR region of DCK could affect mRNA expression and the levels of Ara-CTP in AML blasts [39] . This may influence the response to AraC treatment, but the differences indicated here may also be related to the younger age of our T/C patients.
In summary, the clinical relevance of our findings on the cN-II and DCK SNPs is unclear, and warrants further investigation.
Conclusions
Our 
Supplemental data A
Supplemental data A contains Kaplan Meier survival curves with data for FLT3 and CDA SNPs 79A>C and -451C>T, without censoring at time of bone marrow transplantation (Figure 1-3) .
Distributions of patient characteristics in the entire material and in CDA, cN-II and DCK genotype subgroups are presented in Table I . Subgroup comparisons (independent samples Mann-Whitney U test and Chi 2 or Fisher's exact test) revealed no significant differences in terms of mean age or distributions of gender, FLT3-ITD, NPM1 mutation, treatment (chemotherapy or chemotherapy followed by allo-SCT), or treatment response (CR/non-CR) across CDA or cN-II genotypes. DCK T/C patients were significantly younger than T/T patients, and were more frequently transplanted. 
0.001
a Chemotherapy followed by allo-SCT compared to chemotherapy alone; b compared to CDA 79A/A+A/C; c compared to CDA -451C/C+C/T; d compared to 79A/A or A/C and -451C/C or T/T a Dnr = Daunorubicine; AraC = Cytarabine; 6-TG = 6-thioguanine; Ida = Idarubicine; Cda = Cladribine; Eto = etoposide; FaraA = Fludarabine; G-CSF = Granulocyte-colony stimulating factor; Mitox = Mitoxantrone; mylotarg= Gemtuzumab ozogamicin. b CR = complete remission 
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